chronic kidney disease

Interim results showed that sibeprenlimab demonstrated a statistically significant and clinically meaningful reduction in 24-hour…

Clinical trials have consistently shown empagliflozin’s efficacy in reducing cardiovascular mortality, heart failure…

The approval was based on data from a late-stage study, which showed that Ozempic helped cut the risk of death from chronic kidney…

The study could be of high clinical value to nephrologists who are seeking an optimal treatment of choice for IgAN patients, which…

Study reveals steady annual increase in CKD prevalence, driven by ageing populations and improved diagnosis rates in major markets…

Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating…

Sun Pharma to market the drug under the brand name Lyvelsa

The drug will be marketed by Sun Pharma under the brand name RYTSTAT. Zydus continues to market the drug under the brand name…

Unlike CKD, which arises from old age, diabetes, cardiovascular disease, and other medical problems, patients with CKDu do not…

Forxiga is the first-ever approved medicine for the treatment of the disease in Japan